{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T07:10:34Z","timestamp":1773645034960,"version":"3.50.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Isavuconazole (ISA) is recommended as the first-line therapy for pulmonary aspergillosis. In intensive care unit (ICU) patients, ISA exhibits enhanced clearance and a larger volume of distribution but lower plasma concentrations, indicating the need for plausible dose adjustment. However, current evidence regarding off-label ISA dosing regimens for ICU patients is restricted to pharmacokinetic prediction modeling, with no published clinical studies available to date. In this case, a prolonged ISA-loading dosing regimen was applied to address previous standard ISA treatment failures; thereby, pharmacokinetic steady state was achieved with serial therapeutic drug monitoring (TDM)-guided dose optimization. This study illustrated a favorable clinical course associated with TDM-guided dosing adjustment, with no severe adverse reactions. Given the limited sample size, it is critical to investigate the clinical scenario further to adequately provide references for ISA dosing guidelines and TDM strategies for ICU practice.<\/jats:p>","DOI":"10.3389\/fmed.2026.1693726","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T06:38:23Z","timestamp":1773643103000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic drug monitoring-guided optimization of isavuconazole dose for ICU patients with refractory pulmonary aspergillosis: case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Mingyue","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine","place":["Shanghai, China"]},{"name":"Department of Pharmacy, Yantai Yuhuangding Hospital","place":["Yantai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoshuang","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuya","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolan","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjie","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]},{"name":"Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","article-title":"Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study","volume":"6","author":"Schauwvlieghe","year":"2018","journal-title":"Lancet Respir Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41579-025-01180-z","article-title":"Aspergillus fumigatus biology, immunopathogenicity and drug resistance","volume":"23","author":"van de Veerdonk","year":"2025","journal-title":"Nat Rev Microbiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0114-2022","article-title":"Pulmonary aspergillosis: diagnosis and treatment","volume":"31","author":"Lamoth","year":"2022","journal-title":"Eur Respir Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases-estimate precision","volume":"3","author":"Bongomin","year":"2017","journal-title":"J Fungi"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/s1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet (London, England)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13080706","article-title":"Isavuconazole pharmacokinetics in critically ill patients: relationship with clinical effectiveness and patient safety","volume":"13","author":"Mart\u00edn-Cerezuela","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/jof9020211","article-title":"Population pharmacokinetics of isavuconazole in critical care patients with COVID-19-associated pulmonary aspergillosis and Monte Carlo simulations of high off-label doses","volume":"9","author":"Perez","year":"2023","journal-title":"J Fungi"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"7559","DOI":"10.2147\/IDR.S434622","article-title":"Population pharmacokinetics of isavuconazole in adult: a systematic review","volume":"16","author":"Chen","year":"2023","journal-title":"Infect Drug Resist"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/s1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.transproceed.2025.02.047","article-title":"Successful oral isavuconazole monotherapy for invasive pulmonary mucormycosis in kidney transplant recipients: case reports and literature review","volume":"57","author":"Wang","year":"2025","journal-title":"Transplant Proc"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s40262-023-01305-8","article-title":"Population pharmacokinetics of total and unbound isavuconazole in critically ill patients: implications for adaptive dosing strategies","volume":"62","author":"Jansen","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/phar.2850","article-title":"Utility of triazole antifungal therapeutic drug monitoring: insights from the Society of Infectious Diseases Pharmacists: endorsed by the mycoses study group education and research consortium","volume":"43","author":"McCreary","year":"2023","journal-title":"Pharmacotherapy"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/jcph.2212","article-title":"Population pharmacokinetics, exposure-safety, and probability of target attainment analyses for isavuconazole in Japanese patients with deep-seated mycoses","volume":"63","author":"Shirae","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1128\/AAC.00514-16","article-title":"Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL study)","volume":"60","author":"Kovanda","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/1060028020948174","article-title":"Effect of therapeutic drug monitoring and cytochrome P450 2C19 genotyping on clinical outcomes of voriconazole: a systematic review","volume":"55","author":"Lee","year":"2021","journal-title":"Ann Pharmacother"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1242711","DOI":"10.3389\/fgene.2023.1242711","article-title":"The impact of gene polymorphism and hepatic insufficiency on voriconazole dose adjustment in invasive fungal infection individuals","volume":"14","author":"Li","year":"2023","journal-title":"Front Genet"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/jcpt.12835","article-title":"CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in south-east and east Asian populations: a systematic review","volume":"44","author":"Dorji","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.62438\/tunismed.v102i9.4969","article-title":"Distribution of CYP3A4 and CYP3A5 polymorphisms and genotype combination implicated in tacrolimus metabolism","volume":"102","author":"Hannachi","year":"2024","journal-title":"Tunisie Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/jac\/dkad143","article-title":"Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the infectious diseases working party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"78","author":"Stemler","year":"2023","journal-title":"J Antimicrob Chemother"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1693726\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T06:38:23Z","timestamp":1773643103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1693726\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":24,"alternative-id":["10.3389\/fmed.2026.1693726"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1693726","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"article-number":"1693726"}}